Financial Instruments and Fair Value Measurements (Tables)

3 Months Ended

Dec. 26, 2014

Fair Value Disclosures [Abstract]

Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:

	December 26, 2014		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	36.7	$	24.3	$	12.4	$	—
Liabilities:
Deferred compensation liabilities	$	19.1	$	—	$	19.1	$	—
Contingent consideration and acquired contingent liabilities	202.9		—		—		202.9
Foreign exchange forward and option contracts	4.3		4.3		—		—
	$	226.3	$	4.3	$	19.1	$	202.9

	September 26, 2014		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.7	$	22.9	$	12.8	$	—
Liabilities:
Deferred compensation liabilities	$	15.0	$	—	$	15.0	$	—
Contingent consideration and acquired contingent liabilities	202.8		—		—		202.8
Foreign exchange forward and option contracts	0.2		0.2		—		—
	$	218.0	$	0.2	$	15.0	$	202.8

Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities

Balance at September 26, 2014	$	202.8
Accretion expense	2.0
Effect of currency rate change	(1.9		)
Balance at December 26, 2014	$	202.9

Schedule of Carrying Amount and Fair Value of Long-term Debt

The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period:

	December 26, 2014				September 26, 2014
	Carrying Value		Fair Value		Carrying Value		Fair Value
Variable-rate receivable securitization	$	150.0	$	150.0	$	150.0	$	150.0
2.85% term loan due April 2016	2.9		2.9		3.1		3.1
3.50% notes due April 2018	300.0		289.2		300.0		290.2
Term loans due March 2021	1,987.3		1,950.6		1,990.3		1,970.4
4.00% term loan due February 2022	10.0		10.0		10.8		10.8
9.50% debentures due May 2022	10.4		12.6		10.4		14.2
5.75% notes due August 2022	900.0		926.9		900.0		907.3
8.00% debentures due March 2023	4.7		5.3		8.0		10.2
4.75% notes due April 2023	598.4		560.0		598.3		563.8

Schedules of Concentration of Risk

The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales:

	Three Months Ended
	December 26, 2014		December 27, 2013
CuraScript, Inc.	31	%	—	%
McKesson Corporation	15	%	15	%
Cardinal Health, Inc.	13	%	20	%
Amerisource Bergen Corporation	7	%	12	%

The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period:

	December 26, 2014		September 26, 2014
McKesson Corporation	32	%	24	%
Cardinal Health, Inc.	20	%	17	%
Amerisource Bergen Corporation	12	%	13	%
CuraScript, Inc.	10	%	13	%

The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales:

	Three Months Ended
	December 26, 2014		December 27, 2013
Acthar (Specialty Brands)	31	%	—	%
Optiray™ (CMDS)	7	%	13	%
Methylphenidate ER (Specialty Generics)	6	%	10	%